World Library  
Flag as Inappropriate
Email this Article

Selfotel

Article Id: WHEBN0018486348
Reproduction Date:

Title: Selfotel  
Author: World Heritage Encyclopedia
Language: English
Subject: NMDA receptor antagonist, Perzinfotel, Midafotel, Remacemide, Methoxyketamine
Collection: Carboxylic Acids, Nmda Receptor Antagonists, Phosphonic Acids, Piperidines
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Selfotel

Selfotel
Systematic (IUPAC) name
(2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid
Clinical data
Legal status
  • Legal
Identifiers
CAS number  YesY
ATC code ?
PubChem
ChemSpider  N
UNII  YesY
KEGG  YesY
ChEMBL  N
Synonyms Selfotel
Chemical data
Formula C7H14NO5P 
Mol. mass 223.164 g/mol
 N   

Selfotel (CGS-19755) is a drug which acts as a competitive NMDA antagonist, directly competing with glutamate for binding to the receptor.[1] Initial studies showed it to have anticonvulsant, anxiolytic, analgesic and neuroprotective effects,[2][3] and it was originally researched for the treatment of stroke,[4] but subsequent animal and human studies showed phencyclidine-like effects,[5][6][7][8] as well as limited efficacy and evidence for possible neurotoxicity under some conditions,[9][10][11] and so clinical development was ultimately discontinued.[12][13]

References

  1. ^ Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, et al. CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist. Journal of Pharmacology and Experimental Therapeutics. 1988 Jul;246(1):65-75. PMID 2899170
  2. ^ Bennett DA, Lehmann J, Bernard PS, Liebman JM, Williams M, Wood PL, Boast CA, Hutchison AJ. CGS 19755: a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant, anxiolytic and anti-ischemic properties. Progress in Clinical and Biological Research. 1990;361:519-24. PMID 1981269
  3. ^ France CP, Winger GD, Woods JH. Analgesic, anesthetic, and respiratory effects of the competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 in rhesus monkeys. Brain Research. 1990 Sep 3;526(2):355-8. PMID 2257491
  4. ^ Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke. 1995 Apr;26(4):602-5. PMID 7709405
  5. ^ Bennett DA, Bernard PS, Amrick CL, Wilson DE, Liebman JM, Hutchison AJ. Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics. 1989 Aug;250(2):454-60. PMID 2547931
  6. ^ Koek W, Woods JH, Colpaert FC. N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis. Journal of Pharmacology and Experimental Therapeutics. 1990 Jun;253(3):1017-25. PMID 2193142
  7. ^ Lu Y, France CP, Woods JH. Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists. Journal of Pharmacology and Experimental Therapeutics. 1992 Nov;263(2):499-504. PMID 1432686
  8. ^ Baron SP, Woods JH. Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons: CGS 19755 and phencyclidine. Psychopharmacology (Berlin). 1995 Mar;118(1):42-51. PMID 7597121
  9. ^ Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. Journal of Neurosurgery. 1999 Nov;91(5):737-43. PMID 10541229
  10. ^ Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J. Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist. Stroke. 2000 Feb;31(2):347-54. PMID 10657404
  11. ^ Dawson DA, Wadsworth G, Palmer AM. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Research. 2001 Feb 23;892(2):344-50. PMID 11172782
  12. ^ Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurology. 2002 Oct;1(6):383-6. PMID 12849400
  13. ^ Farin A, Marshall LF. Lessons from epidemiologic studies in clinical trials of traumatic brain injury. Acta Neurochirurgica. Supplement. 2004;89:101-7. PMID 15335108
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.